Your browser doesn't support javascript.
loading
Validation of a Mathematical Model Describing the Dynamics of Chemotherapy for Chronic Lymphocytic Leukemia In Vivo.
Guzev, Ekaterina; Jadhav, Suchita Suryakant; Hezkiy, Eleonora Ela; Sherman, Michael Y; Firer, Michael A; Bunimovich-Mendrazitsky, Svetlana.
Afiliación
  • Guzev E; Department of Mathematics, Ariel University, Ariel 4070000, Israel.
  • Jadhav SS; Department of Chemical Engineering, Ariel University, Ariel 4070000, Israel.
  • Hezkiy EE; Department of Molecular Biology, Ariel University, Ariel 407000, Israel.
  • Sherman MY; Department of Molecular Biology, Ariel University, Ariel 407000, Israel.
  • Firer MA; Department of Chemical Engineering, Ariel University, Ariel 4070000, Israel.
  • Bunimovich-Mendrazitsky S; Adelson School of Medicine, Ariel University, Ariel 4070000, Israel.
Cells ; 11(15)2022 07 28.
Article en En | MEDLINE | ID: mdl-35954169
In recent years, mathematical models have developed into an important tool for cancer research, combining quantitative analysis and natural processes. We have focused on Chronic Lymphocytic Leukemia (CLL), since it is one of the most common adult leukemias, which remains incurable. As the first step toward the mathematical prediction of in vivo drug efficacy, we first found that logistic growth best described the proliferation of fluorescently labeled murine A20 leukemic cells injected in immunocompetent Balb/c mice. Then, we tested the cytotoxic efficacy of Ibrutinib (Ibr) and Cytarabine (Cyt) in A20-bearing mice. The results afforded calculation of the killing rate of the A20 cells as a function of therapy. The experimental data were compared with the simulation model to validate the latter's applicability. On the basis of these results, we developed a new ordinary differential equations (ODEs) model and provided its sensitivity and stability analysis. There was excellent accordance between numerical simulations of the model and results from in vivo experiments. We found that simulations of our model could predict that the combination of Cyt and Ibr would lead to approximately 95% killing of A20 cells. In its current format, the model can be used as a tool for mathematical prediction of in vivo drug efficacy, and could form the basis of software for prediction of personalized chemotherapy.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Antineoplásicos Tipo de estudio: Prognostic_studies Idioma: En Revista: Cells Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Antineoplásicos Tipo de estudio: Prognostic_studies Idioma: En Revista: Cells Año: 2022 Tipo del documento: Article